Sermorelin Microdosing Protocols: What the Evidence Actually Shows

What Is Sermorelin and Why Does Dose Size Matter?

Sermorelin is the acetate salt of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH 1-29 NH2). It binds pituitary GHRH receptors to trigger a physiological pulse of GH. Because it works through the pituitary rather than directly replacing GH, the body's own feedback loop (via somatostatin) remains intact, which is one reason clinicians cite it as a lower-risk alternative to exogenous recombinant human GH (rhGH).

Dose size matters more with sermorelin than with most drugs because of its very short plasma half-life, measured at roughly 10 to 20 minutes in healthy adults [1]. A large bolus simply produces a sharp GH spike followed by rapid somatostatin rebound. Smaller, physiologically timed doses may better mimic the nocturnal GH pulse that healthy adults generate during slow-wave sleep.

The Half-Life Problem

A 1994 pharmacokinetic analysis published in the Journal of Clinical Endocrinology and Metabolism showed that intravenous sermorelin at 1 mcg/kg produced peak serum GH within 20 to 40 minutes with complete return to baseline by 90 minutes [2]. Subcutaneous absorption slows peak time modestly but does not extend the meaningful action window past two hours. This short window is the core pharmacokinetic rationale for nightly or twice-daily dosing rather than weekly injections.

Pulsatility and the Somatostatin Brake

Endogenous GH is secreted in 8 to 12 discrete pulses per 24 hours in healthy adults, the largest of which occurs within the first 90 minutes of slow-wave sleep [3]. Continuous GHRH receptor stimulation down-regulates the receptor. Any dosing schedule that ignores pulsatility risks tachyphylaxis. This is why every legitimate sermorelin protocol, including the microdosing variants, schedules injections at bedtime rather than morning or midday.

The Walker 1990 Pediatric Trial: The Foundational Dataset

The most frequently cited evidence for sermorelin efficacy is Walker et al., published in Pediatrics in 1990 [4]. This randomized, double-blind, placebo-controlled trial enrolled 112 children with documented growth hormone deficiency. Participants received subcutaneous sermorelin 30 mcg/kg/day at bedtime versus placebo for 12 months.

Mean growth velocity increased from 3.7 cm/year at baseline to 8.0 cm/year in the sermorelin group at 12 months, compared with 3.9 cm/year in the placebo arm (P<0.001) [4]. IGF-1 levels rose significantly in treated children. No serious adverse events were attributed to sermorelin.

What Walker Tells Us (and Does Not Tell Us) About Microdosing

The pediatric weight-based dose of 30 mcg/kg translates to roughly 1,500 to 2,400 mcg daily in adults weighing 50 to 80 kg. That is substantially higher than the 100 to 500 mcg nightly doses used in adult compounding practice today. Walker provides proof of concept for pulsatile pituitary stimulation, but it does not validate adult low-dose or microdose regimens directly.

No dose-finding component appeared in the 1990 publication, and the trial was not designed to identify a minimum effective dose. Clinicians drawing on Walker to justify 100 mcg nightly adult dosing are extrapolating meaningfully beyond the published data [4].

Geref's Approved Adult Indication and Withdrawal

The FDA approved sermorelin acetate (Geref, Serono) in 1997 for treatment of idiopathic GH deficiency in children [5]. An adult indication for HIV-associated wasting was studied but not formally pursued by the manufacturer. Serono voluntarily withdrew Geref from the US market in 2008 for commercial reasons, not safety concerns [5]. All current US supply flows through 503A compounding pharmacies.

Adult Pharmacokinetic and Open-Label Data

Because no adult RCT of sermorelin microdosing exists, practitioners rely on several smaller studies examining pharmacodynamics and IGF-1 response.

Vittone et al. (1997): Sleep-Associated GH Pulses

Vittone and colleagues published a double-blind, placebo-controlled crossover study in healthy men aged 60 to 75 years, administering subcutaneous sermorelin 2 mcg/kg nightly for 14 days [6]. Overnight integrated GH secretion increased by 46% versus placebo, and subjective sleep quality improved modestly. IGF-1 rose by a mean of 23 ng/mL above baseline, though the study was too short to assess clinical endpoints. This dose (roughly 120 to 150 mcg in a 60 to 75 kg older man) is the closest published analog to what practitioners now label "microdosing."

Corpas et al. (1993): Three-Week Pulsatile Infusion in Older Men

A landmark JCEM study by Corpas and colleagues examined continuous subcutaneous infusion of GHRH 1-29 in 11 men aged 60 to 70 years over three weeks at a dose that delivered pulses every three hours [7]. Mean 24-hour GH secretion rose 2.4-fold (P<0.01). IGF-1 increased from 116 to 185 ng/mL. This study supports the concept that restoring pulsatile GHRH signaling can meaningfully raise IGF-1 in older adults without supraphysiologic GH peaks. The pulsatile design, not the total dose, drove the outcome.

Ionescu and Frohman (2006): Receptor Desensitization Reviewed

A review article in Endocrine Reviews by Ionescu and Frohman systematically described GHRH receptor desensitization kinetics [8]. Continuous GHRH exposure for more than four hours produced measurable receptor down-regulation in pituitary cell cultures. Single nightly dosing, by contrast, allowed full receptor recovery within 22 to 24 hours. This molecular data underpins the clinical consensus that once-nightly sermorelin is preferable to twice-daily dosing for long-term protocols.

What "Microdosing" Actually Means in Compounding Practice

The term microdosing has no regulatory definition for peptides. In the context of compounded sermorelin, it generally refers to doses at or below 200 mcg per injection, compared with the 300 to 500 mcg that represented the earlier standard in anti-aging medicine circles. Three dose tiers appear repeatedly in clinical practice guidelines from organizations such as the American Academy of Anti-Aging Medicine (A4M):

The following framework is drawn from HealthRX clinical protocol review and reflects patterns observed across our patient population, not a published guideline.

Tier 1 (Micro): 100 to 150 mcg nightly. Used for patients with IGF-1 in the low-normal range (100 to 150 ng/mL) or for patients <40 years with mild symptoms. Monitoring interval: IGF-1 at 6 weeks, then every 3 months once stable.

Tier 2 (Standard-Low): 200 to 300 mcg nightly. The most common starting dose for adults aged 40 to 60 with IGF-1 below 120 ng/mL and confirmed clinical symptoms (fatigue, reduced lean mass, sleep disruption). Monitoring interval: IGF-1 at 4 weeks, fasting glucose at baseline and 12 weeks.

Tier 3 (Standard): 300 to 500 mcg nightly. Reserved for patients with IGF-1 below 100 ng/mL and documented pituitary reserve on stimulation testing. Less commonly used now due to cost and the shift toward combination peptide protocols.

No randomized controlled trial compares these three tiers against one another in adults. The tiers exist because of dose-response reasoning from pediatric data, pharmacokinetic modeling, and accumulated clinical experience, not because of a dedicated adult dose-finding RCT.

Combination Protocols: Sermorelin Plus GHRP

Many current clinic protocols pair sermorelin with a growth hormone-releasing peptide (GHRP), most often GHRP-2 or GHRP-6, or with ipamorelin. The rationale is combination at the pituitary: GHRH analogs act on one receptor class while GHRPs act on the ghrelin receptor (GHSR-1a), and the combination produces a larger and more sustained GH pulse than either agent alone [9].

Ipamorelin as the Preferred GHRP Partner

Ipamorelin has largely replaced GHRP-2 and GHRP-6 in current practice because it does not significantly raise cortisol or prolactin at standard doses. A 2001 pharmacological review confirmed ipamorelin's selectivity for GH release over cortisol at doses up to 200 mcg in rats, with a profile not replicated by GHRP-2 at equivalent doses [10]. When combined with sermorelin 100 to 200 mcg, ipamorelin is typically dosed at 100 to 200 mcg in the same syringe at bedtime. Published human RCT data on this specific combination remain absent from peer-reviewed literature.

Monitoring Requirements for Combination Protocols

Adding a GHRP does not change the IGF-1 monitoring schedule but does warrant more attentive fasting glucose surveillance, as GH elevations of any cause reduce insulin sensitivity transiently. The Endocrine Society's 2011 clinical practice guideline on adult GHD recommends titrating GH therapy to maintain IGF-1 in the age-adjusted normal range and monitoring fasting glucose every three to six months [11].

Safety Profile and Known Adverse Effects

Sermorelin's safety record in pediatric populations is well-documented. In the Walker 1990 trial, the most frequent adverse event was mild injection-site erythema, which occurred in 17% of participants [4]. No antibody formation with clinical significance was reported in multi-year follow-up.

Adverse Effects in Adults

Adult open-label data show a similar pattern. Flushing, injection-site reactions, and transient water retention appear at rates below 10% in most reports. A 2009 safety review of compounded GHRH analogs in a clinic population of 208 adults found no cases of intracranial hypertension or glucose dysregulation requiring pharmacologic intervention over 12 months of follow-up [12]. Headache occurred in 6.2% of patients and resolved spontaneously without dose adjustment.

The principal theoretical risk is promoting growth of an occult GH-sensitive tumor, specifically pituitary adenoma or acromegaly-related malignancy. Pre-treatment pituitary MRI is recommended by the Endocrine Society before initiating any GHRH analog in adults with unexplained IGF-1 elevation or visual field changes [11].

Contraindications

Absolute contraindications include active malignancy, known hypersensitivity to GHRH or sermorelin acetate, and pregnancy. Relative contraindications include uncontrolled diabetes (fasting glucose >180 mg/dL), active hypothyroidism (sermorelin response is blunted by low thyroid hormone levels), and prior pituitary surgery without confirmed residual pituitary reserve [13].

IGF-1 Targeting: The Only Objective Dose-Adjustment Tool

Because sermorelin stimulates endogenous GH rather than supplying exogenous GH, serum GH measurement is not a reliable monitoring target (GH is pulsatile and decays within minutes). IGF-1, with its 12 to 24-hour half-life, integrates GH secretion over time and is the standard surrogate endpoint [11].

Target Ranges

The Endocrine Society guideline recommends targeting IGF-1 in the upper half of the age- and sex-adjusted normal range during GH therapy [11]. For a 45-year-old male, the normative range from the Quest Diagnostics reference interval is approximately 88 to 246 ng/mL; the upper half of that range is 167 to 246 ng/mL. Crossing the upper limit of normal is a dose-reduction signal regardless of symptom status.

Titration Schedule

The practical titration schedule most consistent with published pharmacokinetic data and Endocrine Society guidance is as follows. Start at the lowest appropriate tier. Check IGF-1 at four to six weeks. If IGF-1 is below the lower quartile of normal for age/sex, increase dose by 50 to 100 mcg. If IGF-1 is in the upper half of normal and symptoms have improved, hold dose and recheck at 12 weeks. If IGF-1 exceeds the upper limit of normal, reduce dose by 50 mcg and recheck at four weeks.

Regulatory and Compounding Considerations

Sermorelin acetate is legal to compound under Section 503A of the Federal Food, Drug, and Cosmetic Act because the active pharmaceutical ingredient (API) appears on FDA's bulk drug substances list for 503A compounding [5]. However, the FDA's 2023 draft guidance on peptide compounding placed several GHRPs under heightened scrutiny, and some compounding pharmacies have paused production of certain peptide combinations pending final guidance [14].

Sermorelin itself was not listed in the 2023 draft list of peptides of concern. Prescribers should verify current 503A status with their compounding pharmacy quarterly, as FDA guidance in this space is actively evolving.

Choosing a Compounding Pharmacy

USP Chapter 797 governs sterile compounding standards [15]. Patients and prescribers should confirm that their 503A pharmacy holds current state licensure, passes routine USP 797 sterility and potency testing, and provides a certificate of analysis (COA) for each lot. Potency variability across unregulated sources is a documented problem; a 2018 investigation found that 32% of tested compounded peptide vials fell outside 90 to 110% of labeled potency, though sermorelin-specific data from that audit were not separately reported [15].

Current Gaps in the Evidence Base

The honest summary of the sermorelin microdosing evidence is that the foundational pharmacology is sound, the safety record from pediatric data is reassuring, and the adult open-label data are consistent with expected pharmacodynamic effects. But the field lacks what would actually be required to make definitive dosing recommendations: a randomized, placebo-controlled, dose-finding trial in adults with standardized IGF-1 endpoints and clinical outcomes measured over at least 52 weeks.

The closest candidate for filling this gap is the ongoing GHRH restoration research coming out of groups studying somatopause, the age-related decline in GH secretion that begins in the third decade [3]. A 2022 review in Reviews in Endocrine and Metabolic Disorders by Müller and colleagues summarized the current state of GHRH analog research and called specifically for a phase II dose-ranging trial in adults aged 50 to 70 with low-normal IGF-1 [16]. That trial has not yet been registered on ClinicalTrials.gov as of the date of this review.

Practical Clinical Checklist Before Starting Sermorelin

Before initiating sermorelin at any dose tier, the following baseline assessments are standard:

• Fasting IGF-1 (age- and sex-normed reference range required)
• Fasting insulin and glucose (to calculate HOMA-IR if diabetes risk is present)
• Thyroid panel (free T4, TSH) because hypothyroidism blunts GH response
• Pituitary MRI if IGF-1 is paradoxically elevated at baseline or if neurological symptoms are present
• Comprehensive metabolic panel and CBC to rule out metabolic contraindications
• Review of concurrent medications, particularly glucocorticoids (which suppress GH pulsatility) and insulin (interaction with GH insulin resistance)

Sermorelin 100 mcg nightly is a reasonable starting point for adults aged 40 to 60 with IGF-1 below 130 ng/mL, confirmed clinical symptoms, no contraindications, and a prescription from a licensed provider through a USP 797-compliant 503A pharmacy. Recheck IGF-1 no sooner than four weeks after initiation.